Sichuan Hebang Biotechnology Corporation Limited (SHA:603077)
China · Delayed Price · Currency is CNY 2.380
-0.070 (-2.86%)
At close: Feb 13, 2026
SHA:603077 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,525 | 8,412 | 8,707 | 12,941 | 9,928 | 5,232 |
Other Revenue | 135.11 | 135.11 | 117.15 | 97.73 | 59.66 | 29.16 |
| 7,660 | 8,547 | 8,824 | 13,039 | 9,987 | 5,261 | |
Revenue Growth (YoY) | -16.77% | -3.14% | -32.32% | 30.55% | 89.85% | -11.87% |
Cost of Revenue | 7,186 | 8,010 | 6,823 | 7,492 | 5,874 | 4,345 |
Gross Profit | 474.12 | 537.18 | 2,001 | 5,547 | 4,113 | 916.12 |
Selling, General & Admin | 487.43 | 492.99 | 456.82 | 871.3 | 344.56 | 315.52 |
Research & Development | 20.48 | 30.63 | 47.35 | 67.93 | 33.31 | 39.68 |
Other Operating Expenses | 52.23 | 63.39 | 60.72 | 110.17 | 89.1 | 43.9 |
Operating Expenses | 573.62 | 587.61 | 579.06 | 1,061 | 462.95 | 393.59 |
Operating Income | -99.5 | -50.43 | 1,422 | 4,486 | 3,651 | 522.54 |
Interest Expense | -92.94 | -66.99 | -24.37 | -51.43 | -77.82 | -82.16 |
Interest & Investment Income | 57.9 | 47.05 | 135.57 | 44.52 | 36.31 | 28.04 |
Currency Exchange Gain (Loss) | 4.85 | 4.85 | -1.87 | 5.22 | -14.7 | -32.72 |
Other Non Operating Income (Expenses) | -20.85 | -5.43 | -10.64 | -1.55 | -14.91 | -9.52 |
EBT Excluding Unusual Items | -150.54 | -70.95 | 1,520 | 4,482 | 3,579 | 426.17 |
Impairment of Goodwill | - | - | - | -66.07 | - | - |
Gain (Loss) on Sale of Investments | -8.63 | -5.67 | - | - | - | - |
Gain (Loss) on Sale of Assets | 2.3 | 1.04 | 0.69 | 36.99 | -1.23 | 6.67 |
Other Unusual Items | 9.9 | 9.9 | 14.91 | 25.31 | 0.2 | -417.03 |
Pretax Income | -154.76 | -65.68 | 1,536 | 4,479 | 3,578 | 15.81 |
Income Tax Expense | 35.08 | 5.06 | 257.27 | 668.32 | 551.88 | 12.9 |
Earnings From Continuing Operations | -189.84 | -70.74 | 1,279 | 3,810 | 3,027 | 2.91 |
Minority Interest in Earnings | 93.09 | 102.21 | 4.54 | -3.43 | -8.03 | 38.03 |
Net Income | -96.75 | 31.46 | 1,283 | 3,807 | 3,018 | 40.94 |
Net Income to Common | -96.75 | 31.46 | 1,283 | 3,807 | 3,018 | 40.94 |
Net Income Growth | - | -97.55% | -66.29% | 26.12% | 7272.47% | -92.08% |
Shares Outstanding (Basic) | 8,055 | 8,280 | 8,706 | 8,697 | 8,436 | 8,530 |
Shares Outstanding (Diluted) | 8,055 | 8,504 | 8,706 | 8,697 | 8,436 | 8,530 |
Shares Change (YoY) | -3.60% | -2.32% | 0.10% | 3.09% | -1.10% | -1.48% |
EPS (Basic) | -0.01 | 0.00 | 0.15 | 0.44 | 0.36 | 0.00 |
EPS (Diluted) | -0.01 | 0.00 | 0.15 | 0.44 | 0.36 | 0.00 |
EPS Growth | - | -97.49% | -66.32% | 22.33% | 7354.17% | -91.96% |
Free Cash Flow | -326.52 | -648.3 | -748.4 | 1,708 | 1,462 | 171.76 |
Free Cash Flow Per Share | -0.04 | -0.08 | -0.09 | 0.20 | 0.17 | 0.02 |
Dividend Per Share | - | 0.020 | - | 0.045 | 0.015 | - |
Dividend Growth | - | - | - | 200.00% | - | - |
Gross Margin | 6.19% | 6.29% | 22.67% | 42.54% | 41.19% | 17.41% |
Operating Margin | -1.30% | -0.59% | 16.11% | 34.40% | 36.55% | 9.93% |
Profit Margin | -1.26% | 0.37% | 14.54% | 29.20% | 30.22% | 0.78% |
Free Cash Flow Margin | -4.26% | -7.58% | -8.48% | 13.10% | 14.64% | 3.26% |
EBITDA | 865.02 | 924.25 | 2,410 | 5,400 | 4,282 | 1,165 |
EBITDA Margin | 11.29% | 10.81% | 27.31% | 41.41% | 42.87% | 22.15% |
D&A For EBITDA | 964.53 | 974.69 | 988.23 | 914.52 | 631.02 | 642.95 |
EBIT | -99.5 | -50.43 | 1,422 | 4,486 | 3,651 | 522.54 |
EBIT Margin | -1.30% | -0.59% | 16.11% | 34.40% | 36.55% | 9.93% |
Effective Tax Rate | - | - | 16.75% | 14.92% | 15.42% | 81.60% |
Revenue as Reported | 7,660 | 8,547 | 8,824 | 13,039 | 9,987 | 5,261 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.